Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0ZHYRO)
ADC Name
US20230256114A1 ADC (DAR7)
Synonyms
US20230256114A1 ADC (DAR7)
   Click to Show/Hide
Organization
BIONECURE THERAPEUTICS, INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
7
Antibody Name
Anti-Trop
  Antibody Info 
Antigen Name
Tumor-associated calcium signal transducer 2 (TACSTD2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.59
nM
CVCL_0186
Pancreatic ductal adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.62
nM
CVCL_1603
Gastric tubular adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.77
nM
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
31.75
nM
CVCL_0218
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 500
nM
CVCL_0023
Lung adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 500
nM
CVCL_0062
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.59 nM High TROP2 expression (TROP2 +++)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.62 nM Positive TROP2 expression (TROP2+++/++)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.77 nM Moderate TROP2 expression (TROP2++)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 31.75 nM Low TROP2 expression (TROP2+)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Colon adenocarcinoma Colo205 cells CVCL_0218
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 500 nM Negative TROP2 expression (TROP2-)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Lung adenocarcinoma A549 cells CVCL_0023
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 500 nM Negative TROP2 expression (TROP2-)
Method Description
Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Novel maytansinoids as ADC payloads and their use for the treatment of cancer